{"log_id": 1972900621906832759, "direction": 0, "words_result_num": 33, "words_result": [{"probability": {"variance": 2.4e-05, "average": 0.997783, "min": 0.97514}, "location": {"width": 743, "top": 252, "height": 33, "left": 272}, "words": "已有RA患者发生憩室炎的并发症憩室穿孔事件的报道。对于既往有肠溃疡或憩室炎"}, {"probability": {"variance": 3e-06, "average": 0.998659, "min": 0.992699}, "location": {"width": 784, "top": 292, "height": 33, "left": 230}, "words": "病史的患者,在使用托珠单抗时应格外注意。若患者出现潜在憩室炎并发症的征象(如腹"}, {"probability": {"variance": 3e-06, "average": 0.999023, "min": 0.991337}, "location": {"width": 480, "top": 335, "height": 28, "left": 231}, "words": "痛),则应立即进行检查以早期诊断是否出现胃肠穿孔"}, {"probability": {"variance": 1.4e-05, "average": 0.997292, "min": 0.992038}, "location": {"width": 64, "top": 379, "height": 23, "left": 275}, "words": "肺结核"}, {"probability": {"variance": 5e-06, "average": 0.998619, "min": 0.988061}, "location": {"width": 747, "top": 410, "height": 33, "left": 271}, "words": "按照对类风湿关节炎给予其它生物制剂疗法的建议,在开始托珠单抗治疗前,应对潜"}, {"probability": {"variance": 1.1e-05, "average": 0.998244, "min": 0.980213}, "location": {"width": 782, "top": 449, "height": 33, "left": 233}, "words": "伏性结核感染的患者进行筛选。对于患有潜伏性结核病的患者,在采用托珠单抗进行治疗"}, {"probability": {"variance": 1.2e-05, "average": 0.99775, "min": 0.986847}, "location": {"width": 359, "top": 492, "height": 29, "left": 233}, "words": "之前,应用标准抗分支杆菌疗法进行治疗"}, {"probability": {"variance": 0.000161, "average": 0.98372, "min": 0.971043}, "location": {"width": 46, "top": 535, "height": 25, "left": 276}, "words": "疫苗"}, {"probability": {"variance": 0.000293, "average": 0.9964, "min": 0.89374}, "location": {"width": 746, "top": 567, "height": 32, "left": 274}, "words": "活疫苗和减毒活疫苗不应与托珠单抗同时使用,因为关于这方面的临床安全性尚未明"}, {"probability": {"variance": 0, "average": 0.999824, "min": 0.999824}, "location": {"width": 22, "top": 615, "height": 23, "left": 235}, "words": "确"}, {"probability": {"variance": 0.001481, "average": 0.991673, "min": 0.781204}, "location": {"width": 617, "top": 646, "height": 31, "left": 275}, "words": "没有数据表明接受托珠单抗治疗的患者进行活疫苗接种会导致继发感染"}, {"probability": {"variance": 0.000104, "average": 0.992542, "min": 0.975109}, "location": {"width": 84, "top": 691, "height": 23, "left": 278}, "words": "超敏反应"}, {"probability": {"variance": 0.000622, "average": 0.994709, "min": 0.845345}, "location": {"width": 747, "top": 722, "height": 34, "left": 277}, "words": "已有托珠单抗输注引起严重超敏反应的报道,包括致死性速发过敏反应(见【不良反"}, {"probability": {"variance": 1.2e-05, "average": 0.997486, "min": 0.984738}, "location": {"width": 782, "top": 761, "height": 36, "left": 240}, "words": "应】的临床试验部分)。在上市后治疗中,接受各种剂量托珠单抗的患者均可发生严重超"}, {"probability": {"variance": 3.9e-05, "average": 0.997949, "min": 0.96108}, "location": {"width": 778, "top": 801, "height": 35, "left": 236}, "words": "敏反应和速发过敏反应事件,包括死亡事件,这与是否合用其他关节炎治疗药物,是否于"}, {"probability": {"variance": 6e-06, "average": 0.998535, "min": 0.988342}, "location": {"width": 784, "top": 840, "height": 34, "left": 238}, "words": "输注托珠单抗前接受预防超敏反应药物,以及是否曾发生过超敏反应无关。超敏反应最早"}, {"probability": {"variance": 8e-06, "average": 0.997623, "min": 0.989077}, "location": {"width": 779, "top": 879, "height": 34, "left": 237}, "words": "可发生在托珠单抗的首次输注。使用托珠单抗治疗期间如发生速发过敏反应,应立即采取"}, {"probability": {"variance": 1e-06, "average": 0.999265, "min": 0.996212}, "location": {"width": 785, "top": 918, "height": 34, "left": 238}, "words": "适当的治疗。如发生速发过敏反应或其他严重超敏反应,应立即停止托珠单抗,并永久终"}, {"probability": {"variance": 1e-06, "average": 0.998871, "min": 0.997349}, "location": {"width": 140, "top": 963, "height": 27, "left": 241}, "words": "止托珠单抗治疗"}, {"probability": {"variance": 4.6e-05, "average": 0.996842, "min": 0.975713}, "location": {"width": 223, "top": 1003, "height": 27, "left": 283}, "words": "活动期肝病和肝功能损伤"}, {"probability": {"variance": 8e-05, "average": 0.995306, "min": 0.948222}, "location": {"width": 745, "top": 1037, "height": 33, "left": 282}, "words": "应用托珠单抗,特别是合用甲氨蝶呤时,可能会使肝氨基转移酶升高。所以需慎重考"}, {"probability": {"variance": 1.8e-05, "average": 0.997969, "min": 0.979055}, "location": {"width": 788, "top": 1076, "height": 35, "left": 240}, "words": "虑对有活动期肝病或肝功能损伤的患者进行治疗(见【用法用量】特殊用药说明部分及"}, {"probability": {"variance": 1e-06, "average": 0.99906, "min": 0.997161}, "location": {"width": 250, "top": 1122, "height": 25, "left": 255}, "words": "【不良反应】实验室异常部分"}, {"probability": {"variance": 0.002039, "average": 0.973619, "min": 0.895408}, "location": {"width": 85, "top": 1161, "height": 25, "left": 284}, "words": "病毒激活"}, {"probability": {"variance": 1.4e-05, "average": 0.997787, "min": 0.982238}, "location": {"width": 742, "top": 1192, "height": 35, "left": 283}, "words": "据报道用生物疗法治疗类风湿关节炎时,可致病毒激活(如乙型肝炎病毒)。在托珠"}, {"probability": {"variance": 2e-06, "average": 0.998607, "min": 0.993349}, "location": {"width": 498, "top": 1235, "height": 31, "left": 243}, "words": "单抗临床研究中,对于筛选出的肝炎阳性患者应予以排除"}, {"probability": {"variance": 0.02993, "average": 0.893923, "min": 0.594331}, "location": {"width": 76, "top": 1280, "height": 22, "left": 287}, "words": "脱髓鞘病"}, {"probability": {"variance": 1.7e-05, "average": 0.997819, "min": 0.97488}, "location": {"width": 747, "top": 1310, "height": 35, "left": 282}, "words": "医师应警惕患者中出现的中枢脱髓鞘病发作的潜在征象。目前有关托珠单抗是否会导"}, {"probability": {"variance": 1e-06, "average": 0.998851, "min": 0.995415}, "location": {"width": 364, "top": 1353, "height": 31, "left": 243}, "words": "致潜在中枢脱髓鞘病发作的情况尚不清楚"}, {"probability": {"variance": 2e-06, "average": 0.998233, "min": 0.995133}, "location": {"width": 182, "top": 1395, "height": 26, "left": 288}, "words": "药物滥用与药物依赖"}, {"probability": {"variance": 0.026462, "average": 0.929718, "min": 0.36013}, "location": {"width": 817, "top": 1428, "height": 46, "left": 287}, "words": "尚末进行关于托珠单抗是否有潜在依赖性的研究目前还没有数据表明,托珠搬份"}, {"probability": {"variance": 0, "average": 0.99959, "min": 0.999139}, "location": {"width": 145, "top": 1474, "height": 26, "left": 245}, "words": "疗会导致依赖性"}, {"probability": {"variance": 3e-06, "average": 0.998537, "min": 0.994956}, "location": {"width": 222, "top": 1512, "height": 26, "left": 294}, "words": "对驾驶和机械操作的影响"}], "language": 3}